- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05476588
Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform (TAPS-ESP)
January 23, 2026 updated by: Baylor Research Institute
The goal of this study is to validate the TAPS-ESP as a screen and assessment that can be used in primary care for the screening and treatment of substance use.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This Phase II study seeks to conduct further research to validate the TAPS-ESP as a Spanish language version of the screening and brief assessment and pave the way for its broad dissemination in the healthcare system.
The investigators will use a novel application of a Type 1 hybrid effectiveness-implementation design, adapted to a screening validation study.
The investigators will conduct a large-scale study to validate the TAPS-ESP against established diagnostic and biomarker metrics, replicating the design of the seminal English-language TAPS study.
Study Type
Interventional
Enrollment (Actual)
1000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor Scott and White Community Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 18 or older
- Current patient of the clinic
- Spanish-language preferred
- Ability to read Spanish
Exclusion Criteria:
- Unable to provide informed consent
- Inability to comprehend or read Spanish
- Inability to self-administer the iPad tool due to physical limitations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Self-Administration followed by Interviewer-Administered
Screening and validation of assessment tool translated into Spanish
|
Screening and validation of assessment tool translated into Spanish
|
|
Active Comparator: Interviewer-Administered followed by Self-Administration
Screening and validation of assessment tool translated into Spanish
|
Screening and validation of assessment tool translated into Spanish
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tobacco, Alcohol, Prescription drug, and illicit Substance Use Tool-Electronic Spanish Platform (TAPS-ESP) primary criterion validation against the modified World Mental Health Composite International Diagnostic Interview (CIDI) in Spanish
Time Frame: 1 year
|
TAPS-ESP is a two-stage screening and assessment tool that first screens for 4 broad substance abuse categories (tobacco, alcohol, prescription drug misuse, and illicit substances), then branches to the assessment for specific risks related to an array of substances.
TAPS-ESP scores will be validated against the modified World Mental Health Composite International Diagnostic Interview (CIDI) including alcohol, tobacco, and 9 substance categories.
The CIDI items mapped to the diagnostic criteria for each substance will serve as the primary criterion standard for validation of the TAPS-ESP.
For detecting CIDI-derived substance use disorder (SUD) diagnosis, we will examine TAPS-ESP cut-points for the 4-item screener and the assessment in detecting problem severity defined by CIDI for detecting different tiers of substance use: Problem use (1+ criteria), SUD (2+ criteria), and moderate-to-severe SUD (4-11 criteria).
Detection of SUD will be the primary outcome for each substance category.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) for concurrent and convergent validity of the TAPS Tool
Time Frame: 1 year
|
The ASSIST was developed for the World Health Organization to screen for alcohol, tobacco, and drug use in medical care settings.
For each substance, the use dimensions include lifetime use, past 3 month use, urges or cravings to use, and adverse consequences from use, as well as concerns expressed by family or friends about use (lifetime, past 3 months), failed attempts to control, cut down, or stop use (lifetime, past 3 months), and drug injection (lifetime, past 3 months).
The ASSIST provides substance-specific risk scores 9 substance classes, with scores of 1-3 corresponding to low risk, 4-26 (10-26 for alcohol) to moderate risk, and 27 or higher to high risk.
|
1 year
|
|
Drug Abuse Screening Test (DAST-10) for concurrent and convergent validity of the TAPS Tool
Time Frame: 1 year
|
The DAST-10 is a ten-item yes/no screen for general drug use problems (not including alcohol).
Each item is worth one point, and respondents are tiered into risk categories based on score, with more intensive assessment recommended at a score of 6 or higher.
It has been widely used in the substance use field, but does not distinguish between types of drugs used.
A Spanish language version has been developed.
|
1 year
|
|
CAGE (Cut Down, Annoyed, Guilty, Eye-Opener) for concurrent and convergent validity of the TAPS
Time Frame: 1 year
|
The CAGE is a rapid alcoholism screening test comprised of four yes/no questions (Cut Down, Annoyed, Guilty, Eye-Opener) for which ONE yes answer to any of the four items indicates DSM-IV alcohol abuse or dependence.
A Spanish language version was validated in both Spain and the US, where it performed well in identifying DSM-IV alcohol abuse or dependence among Latinx primary care patients.
|
1 year
|
|
Alcohol Use Disorders Identification Test (AUDIT) for concurrent and convergent validity of the TAPS
Time Frame: 1 year
|
The AUDIT is a 10-item questionnaire which covers the domains of alcohol consumption, drinking behavior, and alcohol-related problems.
It was developed from a six-country World Health Organization collaborative project as a screening instrument for hazardous and harmful alcohol consumption.
Responses to each of the 10 questions are scored according to a frequency rating of 0 (never) to 4 (daily), giving the entire questionnaire a possible score of 40.
A score of 8 or more indicates harmful or hazardous alcohol use.
A Spanish language version of the AUDIT is available.
|
1 year
|
|
Fagerstrom Test for Nicotine Dependence (FTND) for concurrent and convergent validity of the TAPS
Time Frame: 1 year
|
The FTND is comprised of six questions scored on a point system, with total scoring summing between 0 and 10.
Higher scores indicate heavier reliance on nicotine.
The FTDN has been widely used in the tobacco field for decades.
It has been found to be internally consistent and an acceptable way to measure nicotine/tobacco dependency.
The FTND has been translated into Spanish and validated.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Katherine Sanchez, PhD, Baylor Scott and White Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2022
Primary Completion (Actual)
March 14, 2024
Study Completion (Actual)
March 14, 2024
Study Registration Dates
First Submitted
July 1, 2022
First Submitted That Met QC Criteria
July 25, 2022
First Posted (Actual)
July 27, 2022
Study Record Updates
Last Update Posted (Actual)
January 26, 2026
Last Update Submitted That Met QC Criteria
January 23, 2026
Last Verified
October 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Behavior
- Alcoholism
- Substance-Related Disorders
- Tobacco Use
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Diagnostic Techniques and Procedures
- Diagnosis
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Health Services
- Health Care Facilities Workforce and Services
- Preventive Health Services
- Diagnostic Services
- Health Surveys
- Surveys and Questionnaires
- Public Health Practice
- Mass Screening
Other Study ID Numbers
- 022-114
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Time Frame
Two years
IPD Sharing Access Criteria
Contact Principal Investigators
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prescription Drug Abuse
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedPrescription Drug Abuse (Not Dependent)United States
-
University of WyomingCompletedPrescription Drug Abuse (Not Dependent)United States
-
Naval Health Research CenterIntelligent Automation, Inc.CompletedPrescription Drug Abuse (Not Dependent)United States
-
Universidade Nova de LisboaCompletedAnxiety | Prescription Drug Abuse and DependencyPortugal
-
Trinity CollegeUniversity of Wyoming; Texas State UniversityCompletedPrescription Drug Abuse (Not Dependent) | Intentional MisuseUnited States
-
University of UtahNational Institute on Drug Abuse (NIDA); University of Cincinnati; Purdue UniversityCompletedOpioid Abuse | Prescription Drug Abuse (Not Dependent)United States
-
Weill Medical College of Cornell UniversityThe Institute for Family Health; New York State Health FoundationCompletedOpioid-Related Disorders | Opioid Use | Opioid Abuse | Prescription Drug Abuse and DependencyUnited States
Clinical Trials on Screening
-
Vastra Gotaland RegionRecruiting
-
Children's Hospitals and Clinics of MinnesotaCompletedFirearm Injury | Firearm Safety | Firearm OwnershipUnited States
-
University of British ColumbiaUniversity of SydneyRecruitingCardiovascular Diseases | End Stage Renal Disease | Kidney Transplantation | Dialysis Related ComplicationCanada, United States, United Kingdom, Germany
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
University of FloridaPatient-Centered Outcomes Research InstituteEnrolling by invitation
-
Peking University People's HospitalSun Yat-sen University; Fudan University; Sun Yat-Sen Memorial Hospital of Sun... and other collaboratorsCompletedBreast Cancer | Bone MetastasesChina
-
National Institute of Allergy and Infectious Diseases...Ohio Department of Health, City of Cincinnati Board of HealthCompleted
-
University of PittsburghNational Institute of Mental Health (NIMH); Kaiser Foundation Research InstituteCompleted
-
University of La LagunaRecruiting
-
University of La LagunaCompletedHepatitis C Virus InfectionSpain